CompletedNCT04693351
A Study to Evaluate the Efficacy and Safety of Adjunctive Troriluzole in OCD
Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Phoenix, United States · Culver City, United States and 82 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: January 29, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 589
- Sponsor
- Biohaven Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Canada, United Kingdom, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04693351
- Official title
Show the full official title
A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
Recruitment & locations
CompletedPhoenix, United States · Culver City, United States · La Jolla, United States
81 more locations
- Lancaster, United States
- Los Angeles, United States
- San Jose, United States
- Santa Ana, United States
- Sherman Oaks, United States
- Upland, United States
- Denver, United States
- Norwich, United States
- Apopka, United States
- Coral Springs, United States
- Fort Myers, United States
- Gainesville, United States
- Jacksonville, United States
- Miami, United States
- Naples, United States
- North Miami Beach, United States
- Palm Beach, United States
- Pinellas Park, United States
- Decatur, United States
- Snellville, United States
- Chicago, United States
- Naperville, United States
- Overland Park, United States
- Towson, United States
- Boston, United States
- O'Fallon, United States
- Missoula, United States
- Cherry Hill, United States
- Brooklyn, United States
- New York, United States
- Raleigh, United States
- Cincinnati, United States
- Dayton, United States
- Kettering, United States
- Middleburg Heights, United States
- Allentown, United States
- Media, United States
- Austin, United States
- Baytown, United States
- Dallas, United States
- DeSoto, United States
- Houston, United States
- Plano, United States
- San Antonio, United States
- Woodstock, United States
- Calgary, Canada
- Chatham, Canada
- Hamilton, Canada
- Kingston, Canada
- Toronto, Canada
- Beijing, China
- Hangzhou, China
- Tianjin, China
- Xiangya, China
- Nanjing, China
- Shanghai, China
- Wuhan, China
- Guangzhou, China
- Chengdu, China
- Shijiazhuang, China
- Milan, Italy
- Naples, Italy
- Pisa, Italy
- Turin, Italy
- Amsterdam, Netherlands
- Leiden, Netherlands
- Barcelona, Spain
- Madrid, Spain
- Oviedo, Spain
- Salamanca, Spain
- Vigo, Spain
- Stockton-on-Tees, United Kingdom
- Stony Stratford, United Kingdom
- Cannock, United Kingdom
- Blackpool, United Kingdom
- Leeds, United Kingdom
- Liverpool, United Kingdom
- Manchester, United Kingdom
- Milton Keynes, United Kingdom
- Swindon, United Kingdom
- Tankersley, United Kingdom
Questions about this study
Who is behind this study?
The study sponsor is Biohaven Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including Troriluzole and Placebo.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me